The Expanding Role of GLP-1 Receptor Agonists in CNS Clinical Research Expert Insights

The Expanding Role of GLP-1 Receptor Agonists in CNS Clinical Research

(GLP-1 RAs), initially developed for the treatment of type 2 diabetes, have rapidly become a…

cogres1July 1, 2025

4 Ways Strategic Site Selection Maximizes the Value Equation Expert Insights

4 Ways Strategic Site Selection Maximizes the Value Equation

In clinical trials, success hinges not just on protocol design and quality data but on…

cogres1April 10, 2025

Expedited Completion of a Complex Driving Study Collaboration Success Stories

Expedited Completion of a Complex Driving Study

Driving In the Fast Lane Discover how CRC leveraged our proprietary driving simulator to swiftly…

cogres1March 26, 2025

Next-Day Effects: Are Medications Leaving Drivers at Risk? Expert Insights

Next-Day Effects: Are Medications Leaving Drivers at Risk?

COMPLIANCE WITH 2017 FDA GUIDANCE FOR EVALUATING DRUG-IMPAIRED DRIVING Prescription and over-the-counter drugs can save…

cogres1December 18, 2024

World Mental Health Day 2024 Inside CRC

World Mental Health Day 2024

Celebrating Progress in Mental Health Care On World Mental Health Day, we reflect on the…

cogres1October 10, 2024

Two FDA Approvals to Advance Migraine Care Collaboration Success Stories

Two FDA Approvals to Advance Migraine Care

Proactive Mitigation to Support Program Success Learn how CRC’s proactive approach and real-time data oversight…

cogres1October 1, 2024

CRC Expands Medical Leadership Team with Appointment of Accomplished Medical Directors Breaking News

CRC Expands Medical Leadership Team with Appointment of Accomplished Medical Directors

Cognitive Research Corporation (CRC), a leading CNS-focused clinical research organization, proudly announces the addition of…

cogres1September 24, 2024

IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders Collaboration Success Stories

IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders

Overcoming Obstacles to Bring a New Standard of Care Discover how CRC’s approach helped a…

cogres1September 17, 2024

FDA Approval: Novel Formulation for Treatment of Schizophrenia Collaboration Success Stories

FDA Approval: Novel Formulation for Treatment of Schizophrenia

Driving FDA Approvals with Precision and Speed Discover how CRC’s expertise in clinical trial management…

cogres1September 11, 2024

Phase I Studies: On Time with Quality Data Collaboration Success Stories

Phase I Studies: On Time with Quality Data

Consistent Early Phase Milestone Achievement Backed by select partnerships with Phase I Specialty Units and…

cogres1June 24, 2024

Tight Timelines: The Biotech Existence Collaboration Success Stories

Tight Timelines: The Biotech Existence

First Patient In 6 Weeks from Written Award Learn how CRC partnered with an emerging…

cogres1June 20, 2024

CRC Appoints Dr. Tom Zoda as Chief Executive Officer Breaking News

CRC Appoints Dr. Tom Zoda as Chief Executive Officer

Cognitive Research Corporation (“CRC”), a leading Central Nervous System (CNS)-focused clinical research and drug development…

cogres1January 11, 2024